Drug Safety and Availability > Advances in FDA's Drug Safety Programs

Drug Safety and Availability > Advances in FDA's Drug Safety Programs





Today the U.S. Food and Drug Administration (FDA) is sharing an update on the many ways the agency’s Center for Drug Evaluation and Research (CDER) helps to protect the American public from risks associated with use of FDA-approved medications. Our latest annual review highlights new CDER initiatives and key safety-related milestones of 2017. Among many other efforts, the report focuses on CDER’s drug safety surveillance programs, safety oversight for generic drugs, new tools and approaches for fighting the opioid crisis, and our actions to help reduce preventable harm from medications.  For more information please see the CDER Drug Safety Priorities 2017 report.